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Abstract
Background: Nivolumab is an immune checkpoint inhibitor specific for the programmed death 1 (PD-1) receptor
that has led to clinical responses in many cancer types. Identifying biomarkers predictive of response to PD-1
blockade is an area of active investigation.
Case presentation: We present a patient with recurrent, metastatic, PD-L1-negative small cell neuroendocrine
carcinoma of the cervix (SCNEC) who experienced a complete response to nivolumab. Though nivolumab was
discontinued over 4 months ago due to treatment-related adverse events, she continues to have no evidence of
disease.
Conclusions: Immune checkpoint inhibitors may be active in neuroendocrine cervical cancer, with potential for
dramatic responses in a modest subset of patients.
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Background
Small cell neuroendocrine carcinoma of the cervix
(SCNEC) is a rare and aggressive histology. It accounts
for less than 2% of cervical cancers [1]. Unlike squamous
cell and adenocarcinoma, SCNEC is more likely to have
lymphovascular space invasion and lymph node involve-
ment at the time of diagnosis [1, 2]. Patients frequently
present with locally advanced tumors or distant metasta-
ses, resulting in poor oncologic outcomes with a 5-year
survival rate estimated at 36.8% for early stage disease
and less than 10% for advanced disease [1, 2]. Given
these poor outcomes, as well as a lack of prospective
data to guide treatment decisions, patients with SCNEC
pose a therapeutic challenge.
SCNEC is morphologically similar to small cell lung
cancer (SCLC) and treatment considerations draw on
studies conducted in small cell lung cancer cohorts. For
early stage disease, multimodal therapy with surgery
followed by adjuvant cisplatin/etoposide with or without
pelvic radiation is favored [1, 2]. More recently, results
from the SCLC cohort of CheckMate 032 were pub-
lished, describing durable responses in a pretreated
patient population with single agent nivolumab or com-
bination nivolumab and ipilimumab (Antonia, 2016
#2913) To date, there are no studies informing treat-
ment of progressive or recurrent SCNEC after failure of
platinum-based therapy [2]. There is an urgent, unmet
clinical need to develop effective treatments.
Nivolumab is an immune checkpoint inhibitor that is
specific for the programmed death 1 (PD-1) receptor.
PD-1 can be expressed transiently or chronically on T
cells depending on the duration of antigen exposure.
The interaction of PD-1 with its ligand, PD-L1 or PD-
L2, results in downstream signaling that inhibits T cell
cytotoxicity and cytokine release. The rationale behind
blockade of the PD-1 pathway is to abrogate an im-
munosuppressive mechanism present in the tumor
microenvironment (TME). In this report, we present
the clinical experience of a woman with recurrent,
metastatic, SCNEC who had a complete response to
treatment with nivolumab.
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Case presentation
A 38-year-old nulligravida with no history of abnormal
pap smears presented to her primary gynecologist with
complaint of malodorous brown vaginal discharge. A pap
smear was performed, which returned positive for adeno-
carcinoma and high-risk human papillomavirus (HPV).
She was subsequently referred to gynecologic oncology
and diagnosed with a Federation of Gynecology and Ob-
stetrics (FIGO) stage IB2 cervical cancer. Biopsies revealed
a high-grade small cell neuroendocrine carcinoma, and
positron emission tomography–computed tomography
(PET/CT) showed no evidence of metastatic disease. Plan
was made for radical surgical excision followed by adju-
vant chemotherapy and radiation.
The patient underwent radical abdominal hysterectomy,
bilateral salpingo-oophorectomy and pelvic lymphadenec-
tomy. Pathology was negative for involvement of the sur-
gical margins, parametria or pelvic lymph nodes. The
primary tumor was 4.5 by 3.3 cm in size and involved half
of the cervical stroma, with lymphovascular space in-
volvement. Her postoperative course was complicated
by a pelvic abscess requiring re-exploration and wash-
out. Following recovery, she was treated with 6 cycles
of cisplatin 80 mg/m2 intravenously (IV) on day 1 and
etoposide 100 mg/m2 IV on day 1, 2 and 3. Chemother-
apy was well tolerated with only grade 1 nausea and
fatigue.
One month after completion of chemotherapy, surveil-
lance pelvic exam was significant for a 1.5-cm, firm,
smooth anterior vaginal wall mass. PET/CT demon-
strated interval development of multiple hypermetabolic
mesenteric deposits, largest measuring 21 mm with a
standard uptake value (SUV) of 10.6. Shortly thereafter,
she was admitted for small bowel obstruction, with im-
aging revealing multifocal progression of the pelvic le-
sions (Fig. 1). Given disease distribution, systemic
chemotherapy was favored over local radiotherapy, and
she received 2 cycles of paclitaxel 135 mg/m2 IV on day
Fig. 3 Complete resolution of all lesions after 6th dose of nivolumab
Fig. 1 Progressive recurrent pelvic disease resulting
in hydronephrosis
Fig. 2 Reduction in lesion size after starting nivolumab
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1 and topotecan 0.75 mg/m2 IV on day 1, 2 and 3. Fol-
lowing cycle 2 of therapy, the patient was admitted for
progressive pelvic pain due disease progression resulting
in obstructive uropathy (Fig. 1). While hospitalized, a
right percutaneous nephrostomy tube was placed, and
palliative pelvic radiation therapy was initiated. The pa-
tient ultimately received a total of 37.5 Gy in 15 frac-
tions directed towards the obstructive lesion along the
right pelvic side wall. The original tumor was sent for
molecular testing to help inform future therapy and ap-
proval for the off-label use of nivolumab was requested
from her insurance provider.
Nivolumab was initiated at a dose of 3 mg/kg IV every
2 weeks prior to molecular characterization of her tumor,
which showed absent PD-L1 expression. After 2 doses,
radiographic imaging demonstrated a decreased in size of
all target lesions (Fig. 2). Concurrently, all cell counts
began to decrease. After 4 doses, the patient reported vi-
sion changes and light sensitivity. She was evaluated by
ophthalmology and diagnosed with severe dry eyes and
pre-glaucoma. Despite standard topical therapies, her
symptoms progressed and the decision was made to dis-
continue treatment for persistent grade 3 ocular toxicity
after the 6th dose. PET/CT obtained 3 weeks after the final
dose demonstrated complete resolution of all target
and non-target lesions (Fig. 3). Cell counts nadired
(grade 2 lymphocytopenia and thrombocytopenia, grade
3 anemia) 5 weeks after cessation of therapy and began
to show significant recovery by week 7. Hematologic
evaluation, inclusive of bone marrow biopsy, failed to
identify an alternate source of her pancytopenia, which
was attributed to nivolumab.
Discussion
We present a patient with recurrent, metastatic, PD-L1-
negative SCNEC who experienced a complete response
to nivolumab therapy. Though nivolumab was discontin-
ued over 4 months ago due to treatment-related adverse
events, she continues to have no evidence of disease.
From a therapeutics standpoint, orphan diseases such
as SCNEC are traditionally unable to keep pace with
more common malignancies. The low likelihood of
achieving sufficient patient numbers for efficacy trials
discourages scientific initiatives specifically designed for
rare tumor types. The typical solution to this problem
has been to extrapolate treatment strategies from more
frequently encountered cancers of the same cell type,
such as SCLC in the case of SCNEC. This practice as-
sumes that cell origin or morphology is the key feature
to predict response to treatment. The National Cancer
Institute – Molecular Analysis for Therapy Choice
(NCI-MATCH) trial is evidence that this thought
process is changing. In this trial, treatment with various
targeted therapies is directed by genetic testing. Patients
with solid tumors or lymphomas that have progressed
following at least one line of standard treatment (or for
which no agreed upon treatment approach exists) are
assigned to a treatment arm based on the DNA sequen-
cing results of their tumor. This strategy recognizes the
heterogeneity that exists not only between different
types of cancer but also between cancers of the same
type.
In the search for predictive biomarkers to immune
checkpoint inhibitors, the prevalence of somatic muta-
tions has been the most promising. From the outset,
mutagen-induced malignancies, namely melanoma and
lung cancer, have had the greatest success in clinical tri-
als. These cancers approach or exceed 10 somatic muta-
tions per megabase, constituting the highest mutation
frequencies of all cancers [3]. It is hypothesized that the
greater the number of somatic mutations, the greater
the number of neoantigens and the more immuno-
genic the tumor. This principle was assessed by Le and
colleagues in a phase II trial designed to evaluate the
clinical activity of pembrolizumab in patients with
progressive metastatic carcinoma with or without
mismatch-repair deficiency, which is associated with a
difference of 10–100 times the number of somatic mu-
tations [4]. They found an immune-related objective
response rate of 40% and immune-related, 20-week
progression-free survival rate of 78% in patients with
mismatch repair–deficient colorectal cancers, com-
pared to 0 and 11%, respectively, in patients with mis-
match repair–proficient colorectal cancers. Patients
with mismatch repair–deficient non-colorectal cancer
had responses similar to those of patients with mis-
match repair–deficient colorectal cancer.
The number of somatic mutations is unlikely to be the
only determinant of tumor immunogenicity. Topalian
and colleagues hypothesize that integrated oncogenic vi-
ruses are uniquely equipped to generate neoantigens that
engage the immune system [5]. While point mutations
or rearrangements of the tumor genome typically gener-
ate a single or limited number of T cell epitopes, the
products of viral oncogenes are completely non-self and
are likely to contain many more potential antigenic pep-
tides for T cell recognition. Moreover, as drivers of
tumorigenesis, products of viral oncogenes are less likely
to be silenced or deleted as a mechanism of immune
evasion. This theory has found support in a phase II trial
of pembrolizumab in advanced Merkle-cell carcinoma
[6]. Merkle-cell carcinoma, a rare but aggressive skin
cancer, has been linked to 2 major causative factors,
ultraviolet (UV) light and Merkle-cell polyomavirus
(MCPyV), whose large T antigen is expressed in tumor
cells and inactivates p53 and Rb. MCPyV-negative, UV-
induced Merkel-cell carcinomas have a median of 1121
mutations per exome, which exceeds the mutational
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burden reported for cancers that have been most re-
sponsive to PD-1 blockade (i.e. melanoma, lung cancers,
GU cancers). In contrast, MCPyV-positive Merkel-cell
carcinomas, with a median of 12.5 mutations per exome,
carry a mutational burden that is below cancers that
have demonstrated a poor response to PD-1 blockade
(i.e. prostate and pancreatic cancers). Among 25 patients
assigned to pembrolizumab 2 mg per kg every 3 weeks,
44% (4 of 9 patients) of those with MCPyV-negative tu-
mors and 62% (10 of 16 patients) of those with MCPyV-
positive tumors had an objective response. In this trial,
neither PD-L1 expression on tumor cells nor infiltrating
immune cells was associated with clinical response to
pembrolizumab.
The best correlate to Merkle-cell carcinoma in an
HPV-associated cancer is head and neck squamous cell
carcinoma (HNSCC). Just as in Merkle-cell carcinoma,
HNSCC may be mutagen-driven (tobacco) or virus-
driven, with the greater mutational burden found in the
virus-negative tumors. In KEYNOTE-012, a phase Ib
trial of pembrolizumab 10 mg per kg every 2 weeks in
patients with PD-L1-positive recurrent or metastatic
HNSCC, overall response rate (ORR) in all patients was
18% (8 of 45 patients), which consisted of 4 of 29 (14%)
patients with HPV-negative tumors and 4 of 16 (25%)
patients with HPV-positive tumors [7]. Similar results
were found in an expansion cohort of PD-L1 positive or
negative patients that received a fixed dose of pembroli-
zumab at a less frequent dosing schedule (200 mg IV
every 3 weeks) [8]. Compared to 14% (15 of 104 pa-
tients) of patients with HPV-negative tumors, 32% (9 of
28 patients) of those with HPV-positive tumors had an
objective response. Nivolumab has also performed well
in recurrent or metastatic HNSCC. In CheckMate-141, a
phase III trial, median overall survival (OS) was
7.5 months among patients who received nivolumab
3 mg per kg every 2 weeks compared to 5.1 months
among patients who received single-agent systemic ther-
apy [9]. There was a median OS difference of 4.7 months
among patients with HPV-positive tumors (9.1 months
in nivolumab group vs 4.4 months in standard-therapy
group; hazard ratio for death, 0.56; 95% CI, 0.32–0.99)
and a difference of 1.7 months among patients with
HPV-negative tumors (7.5 months in nivolumab group
versus 5.8 months in standard-therapy group; hazard
ratio, 0.73; 95% CI, 0.42–1.25).
It remains to be seen whether integrated oncogenic vi-
ruses may ultimately be validated as a predictive biomarker
for immune checkpoint inhibitors. While we await the re-
sults of additional trials examining checkpoint inhibition in
subjects with virus-positive and virus-negative cervical can-
cer (NCT02488759, NCT02257528), it is important to note
that complete responses and sustained responses remain
rare. Of 177 patients in KEYNOTE-012 who were
evaluated by central review, only 5 patients (2.8%), 4 of
which where HPV-positive, demonstrated a complete re-
sponse to therapy. In our patient, we hypothesize that
radiotherapy may have served to sensitize or prime the im-
mune system. Tumor-directed radiotherapy has been
shown to stimulate the immune system by increasing anti-
gen presentation and promoting a proinflammatory tumor
microenvironment (TME), with well-documented changes
in the cytokine milieu and expression of cell surface mole-
cules [10]. These anti-tumor-specific immune responses
may extend to distant, non-irradiated tumor sites, a
phenomenon termed the abscopal effect. Using various
mouse models, the combination of radiotherapy and im-
mune checkpoint inhibitors has not only been shown to
have synergistic effects on the TME [11] but also to extend
survival [12, 13]. Dramatic responses to this combination
have been reported in humans [14] and are being evaluated
in the clinical trial setting (NCT02383212).
Conclusions
Unlike the more common histological types of cervical
cancer, SCNEC is rarely cured, even when diagnosed at
an early stage. Its resistance to traditional therapies,
reflected in the heterogeneity of treatment sequence de-
scribed in the literature, encourages oncologists to look
to novel therapies. Immunotherapy has the capacity to
turn the causative agent, high-risk HPV, into a feature
that may be exploited for clinical benefit. Among recur-
rent, chemotherapy-resistant, metastatic cervical cancer
patients treated with adoptive T-cell therapy (ACT) in-
volving a single infusion of ex vivo–expanded tumor-
infiltrating T cells, HPV reactivity of the infusion product
positively correlated with clinical response [15]. More re-
search is needed to evaluate whether HPV infection is a
predictive biomarker for immune checkpoint inhibitors,
which have the potential for dramatic responses in a mod-
est subset of patients.
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